Kari Tanderup

Kari Tanderup

Auto-generated profile, based on publicly available information

Kari Tanderup

Danish Center for Particle Therapy, Aarhus University Hospital, 8200 N Aarhus, Denmark

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2016 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
ASAlina Sturdza
Alina Sturdza
RPRichard Pötter
Richard Pötter
LFLars Ulrik Fokdal
Lars Ulrik Fokdal
CHChristine Haie-Meder
Christine Haie-Meder
LTLi Tee Tan
Li Tee Tan
JLJacob Christian Lindegaard
Jacob Christian Lindegaard

1 February 2018 in Clinical and Translational Radiation Oncology
Verified
Journal Article
Open access
RPRichard Pötter
Richard Pötter
KTKari Tanderup
Kari Tanderup
Christian KirisitsChristian Kirisits
Christian Kirisits
ALAstrid de Leeuw
Astrid de Leeuw
KKKathrin Kirchheiner
Kathrin Kirchheiner
IJIna Jürgenliemk-Schulz
Ina Jürgenliemk-Schulz
The publication of the GEC-ESTRO recommendations one decade ago was a significant step forward for reaching international consensus on adaptive target definition and dose reporting in image guided adaptive brachytherapy (IGABT) in locally advanced cervical cancer. Since then, IGABT has been spreading, particularly in Europe, North America and Asia, and the guidelines have proved their broad acceptance and applicability in clinical practice. However, a unified approach to volume contouring and reporting does not imply a unified administration of treatment, and currently both external beam radiotherapy (EBRT) and IGABT are delivered using a large variety of techniques and prescription/fractionation schedules. With IGABT, local control is excellent in limited and well-responding tumours. The major challenges are currently loco-regional control in advanced tumours, treatment-related morbidity, and distant metastatic disease. Emerging evidence from the RetroEMBRACE and EMBRACE I studies has demonstrated that clinical outcome is related to dose prescription and technique. The next logical step is to demonstrate excellent clinical outcome with the most advanced EBRT and brachytherapy techniques based on an evidence-based prospective dose and volume prescription protocol. The EMBRACE II study is an interventional and observational multicentre study which aims to benchmark a high level of local, nodal and systemic control while limiting morbidity, using state of the art treatment including an advanced target volume selection and contouring protocol for EBRT and brachytherapy, a multi-parametric brachytherapy dose prescription protocol (clinical validation of dose constraints), and use of advanced EBRT (IMRT and IGRT) and brachytherapy (IC/IS) techniques (clinical validation). The study also incorporates translational research including imaging and tissue biomarkers.

1 April 2012 in Radiotherapy and Oncology
Verified
Journal Article
Open access
JDJohannes C.A. Dimopoulos
Johannes C.A. Dimopoulos
PPPeter Petrow
Peter Petrow
KTKari Tanderup
Kari Tanderup
PPPrimoz Petric
Primoz Petric
DBDaniel Berger
Daniel Berger
RPRichard Pötter
Richard Pötter
The GYN GEC-ESTRO working group issued three parts of recommendations and highlighted the pivotal role of MRI for the successful implementation of 3D image-based cervical cancer brachytherapy (BT). The main advantage of MRI as an imaging modality is its superior soft tissue depiction quality. To exploit the full potential of MRI for the better ability of the radiation oncologist to make the appropriate choice for the BT application technique and to accurately define the target volumes and the organs at risk, certain MR imaging criteria have to be fulfilled. Technical requirements, patient preparation, as well as image acquisition protocols have to be tailored to the needs of 3D image-based BT. The present recommendation is focused on the general principles of MR imaging for 3D image-based BT. Methods and parameters have been developed and progressively validated from clinical experience from different institutions (IGR, Universities of Vienna, Leuven, Aarhus and Ljubljana) and successfully applied during expert meetings, contouring workshops, as well as within clinical and interobserver studies. It is useful to perform pelvic MRI scanning prior to radiotherapy ("Pre-RT-MRI examination") and at the time of BT ("BT MRI examination") with one MR imager. Both low and high-field imagers, as well as both open and close magnet configurations conform to the requirements of 3D image-based cervical cancer BT. Multiplanar (transversal, sagittal, coronal and oblique image orientation) T2-weighted images obtained with pelvic surface coils are considered as the golden standard for visualisation of the tumour and the critical organs. The use of complementary MRI sequences (e.g. contrast-enhanced T1-weighted or 3D isotropic MRI sequences) is optional. Patient preparation has to be adapted to the needs of BT intervention and MR imaging. It is recommended to visualise and interpret the MR images on dedicated DICOM-viewer workstations, which should also assist the contouring procedure. Choice of imaging parameters and BT equipment is made after taking into account aspects of interaction between imaging and applicator reconstruction, as well as those between imaging, geometry and dose calculation. In a prospective clinical context, to implement 3D image-based cervical cancer brachytherapy and to take advantage of its full potential, it is essential to successfully meet the MR imaging criteria described in the present recommendations of the GYN GEC-ESTRO working group.

1 September 2016 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
KTKari Tanderup
Kari Tanderup
LFLars Ulrik Fokdal
Lars Ulrik Fokdal
ASAlina Sturdza
Alina Sturdza
CHChristine Haie-Meder
Christine Haie-Meder
RMRenaud Mazeron
Renaud Mazeron
RPRichard Pötter
Richard Pötter

1 September 2016 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
LFLars Ulrik Fokdal
Lars Ulrik Fokdal
ASAlina Sturdza
Alina Sturdza
RMRenaud Mazeron
Renaud Mazeron
CHChristine Haie-Meder
Christine Haie-Meder
LTLi Tee Tan
Li Tee Tan
KTKari Tanderup
Kari Tanderup

1 January 2014 in Radiotherapy and Oncology
Verified
Journal Article
Open access
Christian KirisitsChristian Kirisits
Christian Kirisits
MRMark J. Rivard
Mark J. Rivard
DBDimos Baltas
Dimos Baltas
FBFacundo Ballester
Facundo Ballester
MBMarisol De Brabandere
Marisol De Brabandere
FSFrank-André Siebert
Frank-André Siebert
A substantial reduction of uncertainties in clinical brachytherapy should result in improved outcome in terms of increased local control and reduced side effects. Types of uncertainties have to be identified, grouped, and quantified. A detailed literature review was performed to identify uncertainty components and their relative importance to the combined overall uncertainty. Very few components (e.g., source strength and afterloader timer) are independent of clinical disease site and location of administered dose. While the influence of medium on dose calculation can be substantial for low energy sources or non-deeply seated implants, the influence of medium is of minor importance for high-energy sources in the pelvic region. The level of uncertainties due to target, organ, applicator, and/or source movement in relation to the geometry assumed for treatment planning is highly dependent on fractionation and the level of image guided adaptive treatment. Most studies to date report the results in a manner that allows no direct reproduction and further comparison with other studies. Often, no distinction is made between variations, uncertainties, and errors or mistakes. The literature review facilitated the drafting of recommendations for uniform uncertainty reporting in clinical BT, which are also provided. The recommended comprehensive uncertainty investigations are key to obtain a general impression of uncertainties, and may help to identify elements of the brachytherapy treatment process that need improvement in terms of diminishing their dosimetric uncertainties. It is recommended to present data on the analyzed parameters (distance shifts, volume changes, source or applicator position, etc.), and also their influence on absorbed dose for clinically-relevant dose parameters (e.g., target parameters such as D90 or OAR doses). Publications on brachytherapy should include a statement of total dose uncertainty for the entire treatment course, taking into account the fractionation schedule and level of image guidance for adaptation. This report on brachytherapy clinical uncertainties represents a working project developed by the Brachytherapy Physics Quality Assurances System (BRAPHYQS) subcommittee to the Physics Committee within GEC-ESTRO. Further, this report has been reviewed and approved by the American Association of Physicists in Medicine.